Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | PAM | P19021 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.39 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995846 | 0.78 | CYP2C19 (0.51) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL8995848 | 0.76 | CYP2C19 (0.57) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL8995849 | 0.76 | CYP2C19 (0.57) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL1716940 | 0.75 | PAM (0.53) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL1716939 | 0.75 | PAM (0.53) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL10619280 | 0.75 | PAM (0.53) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL7453582 | 0.74 | CYP2C19 (0.48) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL10746755 | 0.72 | PAM (0.48) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL9466771 | 0.72 | PAM (0.48) | MMP1MMP9MMP13PAMCYP2C19 | |
| SCHEMBL393358 | 0.72 | PAM (0.42) | MMP1MMP9MMP13PAMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | claimed |
| US-8308892-B2 | Di-cinnamyl compounds and methods for use thereof | DESIGNER MOLECULES, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | DESIGNER MOLECULES, INC. | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090288768-A1 | DI-CINNAMYL COMPOUNDS AND METHODS FOR USE THEREOF | CAD, DBF4, ACMSD | MMP1 2814/4885MMP9 3430/4885MMP13 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.